Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A combined analysis with four additional studies (total: 4,296 cases and 4,299 controls) confirms association with prostate cancer for rs6983267 in the centromeric locus (P = 9.42 x 10(-13); heterozygote odds ratio (OR): 1.26, 95% confidence interval (c.i.): 1.13-1.41; homozygote OR: 1.58, 95% c.i.: 1.40-1.78).
|
17401363 |
2007 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
A combined analysis with four additional studies (total: 4,296 cases and 4,299 controls) confirms association with prostate cancer for rs6983267 in the centromeric locus (P = 9.42 x 10(-13); heterozygote odds ratio (OR): 1.26, 95% confidence interval (c.i.): 1.13-1.41; homozygote OR: 1.58, 95% c.i.: 1.40-1.78).
|
17401363 |
2007 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Analysis of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer association study database alone and in combination with our data provided further evidence for this second prostate cancer risk locus; in the combined analysis, the allele frequencies for rs6983267 differed statistically significantly between case patients and control subjects (P = 1.61 x 10(-9)).
|
17925536 |
2007 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A meta-analysis across 10 studies including our results of four 8q24 variants (rs1442295 and DG8S737-region 1, rs16901979-region 2, and rs6983267-region 3) and prostate cancer risk demonstrated strong associations across a wide array of study designs and populations.
|
18231127 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Multiple newly identified loci associated with prostate cancer susceptibility.
|
18264097 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We genotyped three variants associated with prostate cancer (rs10090154, rs13254738, and rs7000448), one associated with both prostate and colorectal cancer (rs6983267), and one associated with breast cancer (rs13281615) in a series of 1,499 breast cancer cases and 1,390 controls.
|
18349290 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNPs) rs6983561 and rs6983267 showed the strongest evidence of prostate cancer association.
|
18360876 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The rs6983267 G allele did not show significant association with susceptibility to PC (PC vs. non-PC: P = 0.967; OR, 1.00; 95%CI = 0.83-1.21).
|
18726982 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
There was no joint effect between SNPs rs16901979 A and rs6983267 G. These results confirm the significance of these SNPs in prostate cancer etiology in a previously unstudied population who do not undergo prostate cancer screening and are diagnosed with severe disease.
|
18768513 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
One marker, rs6983267 on chromosome 8q24, has been linked to both colon and prostate cancer, and is therefore a good candidate for a multicancer susceptibility marker.
|
19047180 |
2008 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The highest significance in Caucasian men was found for rs6983267; the AA genotype reduced the risk for PCa [odds ratio (OR) = 0.48, 95% confidence interval (CI) = 0.35-0.65, P = 2.74 x 10(-6)].
|
19528667 |
2009 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Forty-nine tagging SNPs including three previously reported significant variants (rs1447295, rs6983267, rs16901979) and seven variants in the 5' upstream region of the MYC proto-oncogene were tested for association with susceptibility to PC and tumor aggressiveness in 596 histologically verified PC cases and 567 ethnically matched controls.
|
19562729 |
2009 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The A allele of rs1447295 was significantly associated with the risk of sporadic prostate cancer (p = 0.04; age-adjusted OR, 1.34), while the G allele of rs6983267 showed a trend towards being a high-risk allele (p = 0.06; age-adjusted OR, 1.27).
|
19602258 |
2009 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A single nucleotide polymorphism (SNP) rs6983267, located within the 8q24 region, is strongly associated with risk of colorectal and prostate cancer.
|
19895682 |
2009 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Correlation between genotypes and biopsy outcome (positive or negative) and Gleason score (≤6 or >6) were studied by univariate and multivariable analysis. rs1447295 and rs6983267 risk variants were found to be associated with the presence of PCa in univariate analysis. rs6983267 genotype remained significantly linked to a positive biopsy (odds ratio [OR] = 1.66, 95% confidence interval [CI]: 1.06-2.59, P = 0.026) in multivariable analysis, but rs1447295 genotype did not (OR = 1.47, 95% CI: 0.89-2.43, P = 0.13).When biopsy outcome was stratified according to Gleason score, risk variants of rs1447295 were associated with aggressive disease (Gleason score ≥7) in univariate and multivariable analysis (OR = 2.05 95% CI: 1.10-3.79, P = 0.023). rs6983267 GG genotype was not related to aggressiveness.
|
21308149 |
2011 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
There was a tendency towards significantly increased risk for SNPs rs1447295 and rs6983267 in men with early-onset prostate cancer.
|
21557270 |
2011 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC.
|
22067658 |
2011 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A highly significant association (odds ratio=2.84 and p-value=0.002) was found between rs6983267 and prostate cancer in the Greek population.
|
22070222 |
2011 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not.
|
22382457 |
2012 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Significant associations were observed for rs4430796 TT with Gleason scores of ≥ 7 (OR = 1.76, 95% CI = 1.14-2.73) and prostate-specific antigen (PSA) levels of ≥ 10 ng/ml at diagnosis (OR = 1.63, 95% CI = 1.01-2.63), as well as for rs6983267 GG with stage 3-4 CaPs (OR = 1.91, 95% CI = 1.01-3.61).
|
22561070 |
2013 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The polymorphism rs6983267 from region 3 of the chromosome 8q24 appears to be a prominent risk factor for PCa and a biomarker for cancer aggressiveness in the group of patients who presented higher levels of PSA at the time of diagnosis.
|
24224612 |
2014 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Genome-wide association scan for variants associated with early-onset prostate cancer.
|
24740154 |
2014 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
|
24753544 |
2014 |
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
These included correlations between an intergenic CpG site at Chr8:128393157 and the prostate cancer SNP rs16902094 (ρ = -0.54; P = 9.7 × 10(-7); q = 0.002), a PRNCR1 CpG site at Chr8:128167809 and the prostate cancer SNP rs1456315 (ρ = 0.52; P = 1.4 × 10(-6); q = 0.002), and two POU5F1B CpG sites and several prostate/colorectal cancer SNPs (for Chr8:128498051 and rs6983267, ρ = 0.46; P = 2.0 × 10(-5); q = 0.01).
|
25315430 |
2014 |